Yttrium-based therapy for neuroendocrine tumors

Peptide receptor radionuclide therapy with 90Y-peptides is generally well tolerated. Acute side effects are usually mild; some are related to the coadministration of amino acids and others to the radiopeptide itself. Chronic and permanent effects on target organs, particularly kidneys and bone marrow, are generally mild if necessary precautions are taken. The potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumor masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most used radiopeptide in the first 8 to 10 years of experience. © 2014 Elsevier Inc.